@Article{Ząbek2007,
journal="Reumatologia/Rheumatology",
issn="0034-6233",
volume="45",
number="6",
year="2007",
title="Original paperDynamics of anti-CCP antibodies and COMP level in sera of RA patients treated with leflunomide",
abstract="The usefulness of newly introduced laboratory parameters such as anti-CCP antibody level (specific \„marker\” autoantibody in RA) and cartilage oligomeric matrix protein (COMP) level (a very sensitive marker of cartilage degradation), in comparison with RF-IgM level, laboratory disease parameters (ESR, CRP, RBC, Hb and platelet count) and selected clinical parameters (morning stiffness, count of swollen and painful joints, VAS and DAS-28 score) were analyzed in a group of 34 (randomly selected) leflunomide (LFM) treated RA patients \– formerly unsuccessfully treated with two DMARD-s (also with methotrexate). Significant differences in ESR rate and platelet count, and also in the case of morning stiffness, count of swollen and painful joints, VAS and DAS-28 scores between the group of LFM treated and untreated were observed. Between analyzed serological parameters such as RF-IgM and anti-CCP antibody level no significant differences between groups (untreated  vs  LFM treated) were found. Of note, a statistically significant decrease in COMP level, correlated with improvement of the above analyzed clinical parameters, is observed.",
author="Ząbek, Jakub
and Rell-Bakalarska, Maria
and Rutkowska-Sak, Lidia
and Jaworski, Janusz
and Wojciechowska, Bożena",
pages="325--330",
url="https://www.termedia.pl/Original-paper-Dynamics-of-anti-CCP-antibodies-and-COMP-level-in-sera-of-RA-patients-treated-with-leflunomide,18,9523,1,1.html"
}